NASDAQ:HSCS Heart Test Laboratories (HSCS) Stock Forecast, Price & News $0.44 +0.02 (+4.17%) (As of 04:20 PM ET) Add Compare Share Share Today's Range$0.41▼$0.4650-Day Range$0.38▼$0.9752-Week Range$0.30▼$3.95Volume38,130 shsAverage Volume940,053 shsMarket Capitalization$4.80 millionP/E RatioN/ADividend YieldN/APrice Target$3.15 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Heart Test Laboratories MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside615.9% Upside$3.15 Price TargetShort InterestHealthy0.54% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.59Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.16 out of 5 stars 3.5 Analyst's Opinion Consensus RatingHeart Test Laboratories has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.15, Heart Test Laboratories has a forecasted upside of 615.9% from its current price of $0.44.Amount of Analyst CoverageHeart Test Laboratories has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.54% of the float of Heart Test Laboratories has been sold short.Short Interest Ratio / Days to CoverHeart Test Laboratories has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Heart Test Laboratories has recently decreased by 10.41%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldHeart Test Laboratories does not currently pay a dividend.Dividend GrowthHeart Test Laboratories does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HSCS. Previous Next 3.1 News and Social Media Coverage News SentimentHeart Test Laboratories has a news sentiment score of 1.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Heart Test Laboratories this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for HSCS on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Heart Test Laboratories insiders have not sold or bought any company stock.Percentage Held by Insiders14.60% of the stock of Heart Test Laboratories is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 16.68% of the stock of Heart Test Laboratories is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Heart Test Laboratories is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Heart Test Laboratories is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Heart Test Laboratories (NASDAQ:HSCS) StockHeart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.Read More HSCS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HSCS Stock News HeadlinesSeptember 25, 2023 | finance.yahoo.comHeartSciences to Participate in the Maxim Group Virtual Tech Conference Series: Emerging Growth in A.I.September 21, 2023 | finance.yahoo.comHeartSciences Signs Definitive Agreements with the Icahn School of Medicine at Mount Sinai to Commercialize Artificial Intelligence Cardiovascular AlgorithmsSeptember 29, 2023 | Chaikin Analytics (Ad)This Stock Could Go Up 66% or More.Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.September 14, 2023 | finance.yahoo.comHeartSciences Reports First Quarter Fiscal 2024 Financial ResultsSeptember 11, 2023 | finance.yahoo.comHeartSciences Named Electrocardiography Advancement Specialists of the Year 2023 - USA in the Global Health & Pharma Excellence AwardsAugust 31, 2023 | finance.yahoo.comHeartSciences Signs Distribution Agreement with FJ Medical, DenmarkAugust 24, 2023 | finance.yahoo.comHeartSciences’ MyoVista® wavECGTM Selected to be used in Irish Heart Screening EvaluationAugust 24, 2023 | finance.yahoo.comHeartSciences’ MyoVista® wavECGTM Selected to be used in Irish Heart Screening EvaluationSeptember 29, 2023 | Chaikin Analytics (Ad)This Stock Could Go Up 66% or More.Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.August 17, 2023 | finance.yahoo.comHeartSciences Announces Further Expansion of Artificial Intelligence (AI) Patent PortfolioJuly 19, 2023 | finanznachrichten.deHeart Test Laboratories, Inc.: HeartSciences Provides Business Update and Reports Fiscal 2023 Financial ResultsJuly 19, 2023 | finance.yahoo.comHeartSciences Provides Business Update and Reports Fiscal 2023 Financial ResultsMay 17, 2023 | finance.yahoo.comHeartSciences Named as a Top 10 Healthcare Artificial Intelligence Solutions Provider 2023 by Healthcare Tech Outlook MagazineMay 8, 2023 | finance.yahoo.comHeartSciences to Participate at the Inaugural EF Hutton Global ConferenceApril 17, 2023 | finance.yahoo.comHeartSciences to Present at the Planet MicroCap Showcase: VEGAS 2023March 18, 2023 | finance.yahoo.comHeart Test Laboratories Reports Third Quarter 2023 EarningsMarch 16, 2023 | msn.comHeart Test Laboratories GAAP EPS of -$0.16 beats by $0.02, revenue of $1.95MFebruary 7, 2023 | finance.yahoo.comHeartSciences CEO Invited as Featured Guest on The Big Biz Show, February 7 at 11:45 a.m. Pacific TimeJanuary 23, 2023 | finance.yahoo.comCorrection: HeartSciences CEO to Participate in the Healthcare IT Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest on January 25thJanuary 4, 2023 | finance.yahoo.comHeartSciences Appoints David R. Wells to its Board of Directors, an Experienced Capital Markets and Finance ExecutiveDecember 16, 2022 | finanznachrichten.deHeart Test Laboratories, Inc.: HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2023 Financial ResultsDecember 1, 2022 | finance.yahoo.comHeartSciences and Rutgers University Announce Multi-Year Collaboration to Develop AI-based ECG AlgorithmsNovember 28, 2022 | finance.yahoo.comHeartSciences to Present at the 2022 RHK Disruptive Growth Conference on December 5, 2022November 21, 2022 | finance.yahoo.comHeartSciences to Participate at the Benchmark Discovery One-on-One Investor Conference on December 1, 2022November 10, 2022 | finance.yahoo.comHeartSciences’ MyoVista® Technology Used to Develop AI-ECG Algorithm to Identify Patients at High-Risk of Major Adverse Cardiovascular EventsOctober 25, 2022 | finance.yahoo.comHeartSciences Granted European Patent for Proprietary Electrode and Cable Connections for Use with its AI-Based MyoVista® ECGOctober 20, 2022 | finance.yahoo.comHeartSciences Named as a Top 10 MedTech Startup 2022 by MedTech Outlook MagazineSee More Headlines Receive HSCS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Heart Test Laboratories and its competitors with MarketBeat's FREE daily newsletter. Email Address HSCS Company Calendar Last Earnings7/19/2023Today9/29/2023Next Earnings (Estimated)12/21/2023Fiscal Year End4/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical appliances & supplies Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:HSCS CUSIPN/A CIK1468492 Webheartsciences.com Phone682-237-7781FaxN/AEmployees12Year FoundedN/APrice Target and Rating Average Stock Price Forecast$3.15 High Stock Price Forecast$3.30 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+645.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,350,000.00 Net MarginsN/A Pretax Margin-307,400.00% Return on Equity-4,601.51% Return on Assets-173.97% Debt Debt-to-Equity Ratio2.17 Current Ratio1.07 Quick Ratio0.71 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.05) per share Price / Book-8.45Miscellaneous Outstanding Shares10,920,000Free Float9,327,000Market Cap$4.61 million OptionableNot Optionable Beta4.01 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Andrew Simpson (Age 54)CEO, Pres & Chairman of Directors Comp: $264.14kMs. Danielle Watson (Age 41)CFO & Treasurer Comp: $188.75kMr. Mark T. Hilz (Age 64)COO, Sec. & Director Comp: $263.61kKey CompetitorsNanoVibronixNASDAQ:NAOVBone BiologicsNASDAQ:BBLGPredictive OncologyNASDAQ:POAIWindtree TherapeuticsNASDAQ:WINTEnveric BiosciencesNASDAQ:ENVBView All CompetitorsInstitutional OwnershipRenaissance Technologies LLCBought 12,650 shares on 8/11/2023Ownership: 0.341%AE Wealth Management LLCSold 38,776 shares on 7/10/2023Ownership: 1.079%View All Institutional Transactions HSCS Stock - Frequently Asked Questions Should I buy or sell Heart Test Laboratories stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Heart Test Laboratories in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HSCS shares. View HSCS analyst ratings or view top-rated stocks. What is Heart Test Laboratories' stock price forecast for 2023? 2 equities research analysts have issued 1 year target prices for Heart Test Laboratories' stock. Their HSCS share price forecasts range from $3.00 to $3.30. On average, they predict the company's share price to reach $3.15 in the next twelve months. This suggests a possible upside of 645.7% from the stock's current price. View analysts price targets for HSCS or view top-rated stocks among Wall Street analysts. How have HSCS shares performed in 2023? Heart Test Laboratories' stock was trading at $0.8399 at the start of the year. Since then, HSCS shares have decreased by 49.7% and is now trading at $0.4224. View the best growth stocks for 2023 here. Are investors shorting Heart Test Laboratories? Heart Test Laboratories saw a decline in short interest in the month of September. As of September 15th, there was short interest totaling 37,000 shares, a decline of 10.4% from the August 31st total of 41,300 shares. Based on an average daily trading volume, of 94,900 shares, the days-to-cover ratio is currently 0.4 days. Approximately 0.5% of the shares of the company are short sold. View Heart Test Laboratories' Short Interest. When is Heart Test Laboratories' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, December 21st 2023. View our HSCS earnings forecast. How were Heart Test Laboratories' earnings last quarter? Heart Test Laboratories, Inc. (NASDAQ:HSCS) issued its earnings results on Wednesday, July, 19th. The company reported ($0.16) earnings per share for the quarter. When did Heart Test Laboratories IPO? (HSCS) raised $9 million in an IPO on Wednesday, June 15th 2022. The company issued 1,800,000 shares at a price of $4.50-$5.50 per share. The Benchmark Company served as the underwriter for the IPO. What is Heart Test Laboratories' stock symbol? Heart Test Laboratories trades on the NASDAQ under the ticker symbol "HSCS." How do I buy shares of Heart Test Laboratories? Shares of HSCS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Heart Test Laboratories' stock price today? One share of HSCS stock can currently be purchased for approximately $0.42. How much money does Heart Test Laboratories make? Heart Test Laboratories (NASDAQ:HSCS) has a market capitalization of $4.61 million. The company earns $-6,350,000.00 in net income (profit) each year or ($0.67) on an earnings per share basis. How can I contact Heart Test Laboratories? The official website for the company is heartsciences.com. The company can be reached via phone at 682-237-7781 or via email at hscs@crescendo-ir.com. This page (NASDAQ:HSCS) was last updated on 9/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Heart Test Laboratories, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.